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Abstract
Background: Computed tomography (CT) is the standard procedure for follow-up of non-small-cell lung cancer
(NSCLC) after radiochemotherapy. CT has difficulties differentiating between tumor, atelectasis and radiation
induced lung toxicity (RILT). Diffusion-weighted imaging (DWI) may enable a more accurate detection of vital tumor
tissue. The aim of this study was to determine the diagnostic value of MRI versus CT in the follow-up of NSCLC.
Methods: Twelve patients with NSCLC stages I-III scheduled for radiochemotherapy were enrolled in this
prospective study. CT with i.v. contrast agent and non enhanced MRI were performed before and 3, 6 and 12
months after treatment. Standardized ROIs were used to determine the apparent diffusion weighted coefficient
(ADC) within the tumor. Tumor size was assessed by the longest longitudinal diameter (LD) and tumor volume on
DWI and CT. RILT was assessed on a 4-point-score in breath-triggered T2-TSE and CT.
Results: There was no significant difference regarding LD and tumor volume between MRI and CT (p ≥ 0.6221,
respectively p ≥ 0.25). Evaluation of RILT showed a very high correlation between MRI and CT at 3 (r = 0.8750) and
12 months (r = 0.903). Assessment of the ADC values suggested that patients with a good tumor response have
higher ADC values than non-responders.
Conclusions: DWI is equivalent to CT for tumor volume determination in patients with NSCLC during follow up.
The extent of RILT can be reliably determined by MRI. DWI could become a beneficial method to assess tumor
response more accurately. ADC values may be useful as a prognostic marker.
Keywords: Tomography, Spiral computed, Magnetic resonance imaging, Functional magnetic resonance imaging,
Radiotherapy, Image-guided, Radiation pneumonitis, Lung neoplasms
Background
Stereotactic body radiotherapy (SBRT) has a high cura-
tive potential and offers excellent local tumor control in
inoperable early stage NSCLC [1] while chemoradiother-
apy is the standard treatment for inoperable, locally
advanced NSCLC [2].
In stage III substantial improvements have been
achieved during the past two decades with 5-year
survival rates now surpassing 30% [3]. Yet, even with
effective newer standards in radiotherapy (the integra-
tion of FDG-PET/CT based treatment planning, the
application of involved-field target volume concepts to
spare organs at risk and the use of intensity modulated
radiotherapy [IMRT]) local tumor control still remains
unsatisfactory. An actuarial locoregional recurrence rate
of 40% after 3 years was reported by Garg et al. [4], in
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another retrospective report of Kandi et al. 67 of 137 pa-
tients (48,9%) experienced a locoregional recurrence
after chemoradiotherapy [5]. An early diagnosis of recur-
rence or detecting a lack of tumor response is essential
to provide the patient with an alternative treatment ap-
proach such as immunotherapy. For this reason, surveil-
lance is important for monitoring the primary tumor
site and detecting metastases.
Several oncological societies such as the National
Comprehensive Cancer Network (NCCN) and the
American College of Chest Physicians (ACCP) have gen-
erated guidelines for post-treatment surveillance imaging
of NSCLC [6, 7]. The recommendations stated in these
guidelines are based on low-grade evidence [8] and most
existing studies address post-operative rather than post-
radiation follow up.
The currently available guidelines recommend com-
puted tomography (CT) of the chest as standard modal-
ity every 6–12month after treatment of lung cancer for
the first 2 years. CT is an established method that is eas-
ily available almost anywhere and will quickly generate
high-resolution images with isotropic voxels that allow
reconstructions in all spatial planes. However, follow up
imaging by CT following radiation therapy can be
challenging to interpret, because of radiation induced
lung disease (RILT) or formation of tumor-atelectasis-
complex [9]. In addition, iodine-containing contrast
agent, which in turn carries risks, is obligatory in order
to better evaluate mediastinal and hilar structures.
Thus, an examination which masters the differenti-
ation of tumor atelectasis complex as well as distinguish-
ing RILT versus recurrence would be advantageous. A
suitable method that could fulfill this requirement is
thoracic magnetic resonance tomography (MRI). In par-
ticular, diffusion weighted imaging (DWI) turns out to
be promising. DWI is a technique which measures the
movement of water molecules known as “brownian mo-
tion” using magnetic field gradients. Lesions with high
cell density, like tumor tissue, appear bright in DWI im-
aging due to decreased diffusion. Recently published
studies already pointed out the benefit of DWI in chest
MRI for differential diagnosis of pulmonary nodules [10]
as well as for initial staging of lung cancer and evalu-
ation of lymph node status in particular [11, 12]. Fur-
thermore, a study group could already show a good
correspondence of initial tumor volume determination
when comparing PET-CT and DWI [13]. However, there
is only limited data about the value of DWI in the
follow-up assessment of NSCLC after radiochemother-
apy. In terms of tumor response, there is an ongoing de-
bate about the predictive value of DWI in regard to
apparent diffusion coefficient (ADC).
The aim of our study was to determine the diagnostic
value of MRI, especially DWI, versus CT in the follow-
up of NSCLC patients after radiochemotherapy. In
addition to the assessment of the primary tumor course,
a focus was placed on the evaluation of RILT.
Methods
Study population and inclusion criteria
Eligible patients were at least 18 years old and had a
histological diagnosis of non-metastasized NSCLC
(UICC stages I–III), had no contraindications to MRI,
did not receive any previous antitumoral therapy and
were allocated to receive–depending on tumor stage–ei-
ther SBRT or definitive radiotherapy with concurrent
chemotherapy. Written informed consent was obtained
from all patients prior to study inclusion. This prospect-
ive study was conducted in accordance with the Helsinki
declaration and was approved by the local ethics com-
mittee (blinded for review).
Follow-up interval
The patients received both a planning CT and MRI be-
fore the start of radiotherapy. Follow-up CT and MRI
were performed at 3, 6 and 12months after radiother-
apy. Follow-up CT examinations were performed in an
outpatient setting according to the standard of care. All
MRI examinations were performed at the Department of
Diagnostic and Interventional Radiology. In order to en-
sure the best possible comparability of the two modal-
ities, the time interval between the two examinations
was kept as small as possible. The median interval be-
tween the acquisition of the CT and the MRI was 8 days
(range 5–12 days) for the pretherapeutic examinations,
7 days (range 1–34) for the 3-month follow-up, 7 days
(range 1–33) for the 6-month follow-up and 4 days
(range 0–13) for the 12-month follow-up.
Acquisition of CT and MRI images
Patients received their initial planning CT in the
Department of Radiotherapy and Radiation Oncology.
The planning CT was a Philips BigBoreTM 120 kV
scanner (Philips Medical Systems, Amsterdam, The
Netherlands). Patients received iodinated intravenous
contrast medium adapted to body weight. The slice
thickness was 3 mm, images were acquired during free
shallow breathing. Only patients with stage I NSCLC
designated for SBRT received an additional 4D-CT. Out-
patient follow-up CTs were performed in inspiratory
breath hold and after body weight-adapted administra-
tion of iodinated contrast medium.
All MRI examinations were performed using the same
1.5 T MRI scanner (Magnetom Aera, Siemens, Erlangen,
Germany). A Half Fourier Acquisition Single Shot Turbo
Spin Echo (HASTE) sequence (TE = 91 ms, TR = 1000
ms, Flip-angle = 125°, averages = 1, slice thickness 5 mm,
FOV = 285 × 380 mm, matrix = 320 × 192) was acquired
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in transverse and coronal planes. To generate diffusion-
weighted images a single-shot echo planar diffusion-
weighted sequence with Stejskal-Tanner diffusion
encoding scheme using an inversion recovery for fat sat-
uration (TR = 15,400 ms, TE = 75 ms, TI = 180ms, PAT
factor of 2, 3-scan trace (averaged), averages = 4, slice
thickness 5 mm, FOV = 309 × 380 mm, matrix = 208 ×
128 (interpolated to 208 × 256), no gap) was acquired.
The real voxel size of the sequence was 1.5 × 3 × 5mm3.
Two b-values at b = 0 and b = 800 s/mm2 were acquired.
Fusion Images were composed of the HASTE and the
DWI. ADC maps and additional high b-value images at
b = 1400 s/mm2 were calculated automatically by the
scanner software, based on linear signal decay. Both
HASTE and DWI sequences were acquired with the pa-
tient breathing freely; these sequences were subsequently
coregistered for image fusion.
To ensure adequate image quality, the DWI sequences
were checked by the supervising medical assistant and
the physician on duty immediately after their
acquisition.
In the event of any imaging artifacts, the DWI-
sequences were repeated (in altogether three examina-
tions the DWI had to be repeated due to artifacts).
In addition, a respiratory gated T2-weighted sequence
(TE = 106ms, TR = 3692 ms, Flip- angle = 160°, aver-
ages = 2, 3 mm slice thickness, FOV = 277 × 370 mm,
matrix = 384 × 202) was acquired in a transverse plane.
Assessment of the tumor size, ADC values and RILT
Generally, all indicated tumor measurements relate to
the primary tumor. The tumor size was evaluated ac-
cording to RECIST 1.1. Thus, the longest longitudinal
diameter (LD) of the lesion was measured and classified
accordingly to its treatment response into “stable dis-
ease” (SD), “partial response” (PR), “progressive disease”
(PD) and complete remission (CR). Depending on the
course of the disease either baseline or nadir was used to
compare and classify the tumor response. Furthermore,
the extent of the primary cancer was determined by
volumetric measurement. The tumor volume in its
course was, in contrast to RECIST 1.1, always related to
the baseline.
The examinations were evaluated by two observers
with a work experience of 9 and 22 years in consensus.
To generate the CT-derived tumor volume both soft tis-
sue and lung window were regarded and the tumor was
finally delineated in the lung window. For RECIST-
evaluation, the longest longitudinal diameter of the
primary cancer in lung window was measured. The de-
lineation of the diffusion-weighted tumor volume was
performed on diffusion weighted MR image sets and the
measurement of the longest longitudinal diameter was
also carried out on DWI. The performing observers were
blinded for the corresponding CT tumor diameter and
volume. The DWI-based contours were delineated visu-
ally and secondarily checked and–if necessary–adjusted
for anatomical plausibility on the corresponding T2-
weighted sequence.
DWI was also studied as a functional marker. The
ADC maps were used as functional values. The tumor
region with the lowest ADC was identified by consensus
by the two radiologists and a standardized ROI of 100
mm2 was placed in this area. The ROIs had to be located
completely within the tumor and were standardized to
size for better comparability.
Consequently, the ROI had to be adjusted in some
cases so that the average size of the ROI was 99.13
mm2 ± 6.91. T2-weighted MR images were used as a ref-
erence, to avoid the inclusion of necrotic areas. The
mean and standard deviation as well as minimum and
maximum values of the ROIs were recorded.
Each study was examined for morphological signs of
RILT. A 5-point score established for CT examinations
[14] was adapted to a 4-point score to assess RILT (0 =
no radiation pneumonitis, 1 = reticular lung parenchyma
changes, 2 = inhomogeneous consolidation, 3 = homoge-
neous consolidations). The CT examinations were evalu-
ated in the lung window and the MRI examinations on
respiratory-triggered T2-TSE images by the two observer
pairs. The classification into the respective score was
made by consensus. Furthermore, the interobserver vari-
ability of the longest tumor diameter and the RILT score
was determined.
The evaluation of the longest longitudinal diameters,
ADC values and RILT was done on a PACS workstation
(SECTRA IDS 7 workstation, Sectra AB, Linkoeping,
Sweden). Volume analysis was performed using a med-
ical imaging software (Osirix MD 6.0, Pixmeo Sarl,
Switzerland).
Statistics
Statistical analysis was performed using GraphPad Prism
(Prism® 8 for Mac, Version 8.00, GraphPad Software
Inc., San Diego, CA, USA). Values are displayed as me-
dian and range (min. to max.) because normal distribu-
tion was not assumed. Nonparametric data was further
analyzed with a Wilcoxon matched-pairs signed rank
test. Correlation for non-normal distributed values was
tested using the Spearman correlation test (RS). For
comparison of the 4 ADC timepoints a mixed-effect ana-
lysis was performed with a Tukey test afterwards. Inter-
observer variability was evaluated using weighted kappa
for ordinal variables. The assessment of agreement was
made according to Landis et al. [15]. For continuous
data, reliability was assessed using the intraclass correl-
ation coefficient (ICC), which is commonly considered
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very good when greater than 0.90 [16]. The significance
level was defined as p < 0.05.
Results
Patients’ and treatment characteristics
Twelve patients (3 female, 9 male) with histologically
proven NSCLC were included in the study between
July 2013 and November 2015. The median age was
68.5 years (range 42–79 years). One patient had two
synchronous lesions of NSCLC (in both upper lobes),
which were evaluated separately. TNM stages, histolo-
gies, UICC-stages, the localization of the primary
tumor and follow-up classification according to RECI
ST 1.1 are shown in Table 1. The distribution of
UICC-stages and histology was as follows: IA (n = 3),
IIB (n = 1), IIIA (n = 3) and IIIB (n = 3) and IIIC (n =
2); squamous cell cancer (n = 8), adenocarcinoma (n =
4 whereof two were present in one patient) and ‘not
otherwise specified’ (n = 1). In 3 patients with early
stages (one of them with two lesions) stereotactic
body radiotherapy was indicated. These patients re-
ceived 4 × 12 Gy (equaling a biologically effective dose
for an α/β - value of 10 [BED10] of 105.6 Gy), pre-
scribed to the surrounding 80% isodose line of the
PTV. Definitive radiochemotherapy was planned for
all other patients with locally advanced stages using
intensity modulated radiotherapy (IMRT) with a me-
dian isocenter dose of 60 Gy (range 58–66.6; single
doses 1.8–2.0 Gy). For all patients (median PTV size
of 484 mL [24.5–1407]), dosimetric parameters for or-
gans at risk were as follows (given as median values):
mean lung dose 14.9 Gy (4–20.8), V20 (total lung)
26% (3–30.2), V5 (total lung) 63.5% (17–88), mean
esophageal dose 27.7 Gy (2.1–37.1), mean heart dose
6.85 Gy (0.1–33.5), spinal cord – maximum dose 37.3
Gy (1.8–42.8).
Assessment of tumor size using RECIST 1.1/ LD
Figure 1 shows tumor response in CT and DWI over the
three follow-up examinations.
3-month follow-up
After 3 months, 13 CT and 12 DWI data sets were avail-
able. A total of 12 data pairs were comparable. In one
Table 1 Representation of the TNM stage, histology, the UICC stage, the localization of the primary tumor as well as the
classification of the follow-up investigations according to RECIST 1.1. Note – PEC = squamous cell carcinoma, Adeno = Adeno
carcinoma, SD = stable disease, PD = Progessive Disease, PR = Partial Remission, n.d. = not detectable, Pneumonitis = not
detectable because of severe pneumonitis, m.a. = missed appointment
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patient the tumor could no longer be clearly identified
by DWI; however, in this case, there was no difference
in tumor response regarding RECIST 1.1 due to newly
occurring distant metastasis. When assessing tumor re-
sponse, there were 10 matches between CT and DWI as
follows: PR (n = 6), SD (n = 3) and PD (n = 1). Two cases
were discrepant, as CT classified them as PR and DWI
as SD. However, in both cases of DWI only two percent-
age points were missing in order to classify them also as
PR. A single reverse case in which DWI classified tumor
response as PR and CT classified it as SD occurred.
The median percentage size changes of the tumor
showed no significant difference between CT (− 33.33
[− 72.0–5.0]) and DWI (− 31.86 [− 76.0–13.92) (p =
0.6221).
6 -month follow-up
After 6 months, 8 CT and 7 DWI data sets were
available. A total of 5 data pairs were comparable. One
patient had died of his tumor disease during this follow
up interval.
Another patient left the study because of a resectable
tumor after treatment initiation.
Another patient with SD on CT follow-up did not turn
up for his MRI appointment. In another patient with SD
after CT evaluation, the tumor could no longer be delin-
eated on MRI (CR); retrospectively it could be shown
that this patient was free from recurrence until the end
of the study. Due to a pronounced fibrosis, no evaluation
of the tumor in the right lower lobe was possible in one
patient on CT. Interestingly, no considerable diffusion
restriction could be seen in the corresponding DWI
dataset in this area; however, at this time, in contrast to
the CT scan, a diffusion-restricted lesion on the right
hilar side was detectable; here the patient developed a
recurrence (Fig. 2). In addition, DWI was able to classify
2 patients reliably as PR, whilst no tumor evaluation was
possible on CT for these patients due to pneumonitis.
One patient was scored on CT as a PR, at which time no
tumor was assessable in the DWI. One patient had PD
on both DWI and CT. Three cases were discrepant, as
CT classified them as SD and DWI as PR, whereas the
percentages of the two modalities were in part close to
the threshold between PR and SD. The CT classified one
patient as SD, which the DWI contrarily classified as PD;
retrospectively, the patient developed a recurrence and
died after the study.
The median percentage size changes of the tumor
showed no significant difference between CT (4.23 [−
45.83–68.95]) and DWI (− 35.15 [− 48.46–122.8) (p >
0.99).
12-month follow-up
After 12 months, 3 CT and 4 DWI data sets were avail-
able. A total of 3 data pairs were comparable. In the
meantime, altogether three patients had died; two pa-
tients due to tumor progress and one patient due to ex-
acerbated COPD. One patient did not show up at the
Fig. 1 Representation of the percent change in the longitudinal diameter (LD) 3 (a), 6 (b) and 12 (c) months after initiation of therapy.
Depending on the therapeutic response the reference value used to determine the percentage change in tumor response according to RECIST
1.1 are baseline or Nadir. All three panels show no statistically significant difference in the assessment of the LD. Values are displayed as mean
and SEM
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MRI and the CT appointment, another one missed only
the MRI appointment. Due to a pronounced fibrosis, no
reliable evaluation of the tumor was possible in two pa-
tients on CT images, whereas DWI showed no suspect
signal in these two patients (CR). The clinical course
made it most likely that the diagnosis of CR was correct.
In another case fibrosis did not allow for a clear state-
ment regarding tumor size on CT images. The corre-
sponding DWI showed a PR. Again, this diagnosis was
confirmed by further follow up. Two patients were
scored as SD on CT, whereas being rated as PR by DWI.
However, the CT percentage values of those two patients
Fig. 3 Representation of the percent change in tumor volume 3 (a), 6 (b) and 12 (c) months after initiation of therapy. The reference value used
to determine the percentage change in tumor response is always the baseline. All three panels show no statistically significant difference in the
assessment of the tumor volume. Values are displayed as mean and SEM
Fig. 2 Presentation of the disease process before treatment and in the course of the three follow-ups. a-f shows the MRI sequences inverted DWI
(b-value = 800 s/mm2) and T2-TSE in a transversal plane. G-L shows the corresponding CTs in lung and soft tissue window. The time points 6 and
12months are divided into two anatomical regions (right lower lobe and right centrally). The tumor response after 3 months can be assessed in
the DWI (b) as accurately as in the CT (h). After 6 months, severe radiation pneumonitis develops. Their extent can be determined both by MRI (c)
and CT (i). Within pneumonitis it is difficult to make a statement on tumor response on CT (i). In the DWI (c), however, one can not detect any
suspicious signal in the right lower lobe at this time. In addition, the DWI (d), in contrast to the CT (j) already delineates a suspicious signal on
the right hilum. After 12 months, the findings after 6 months for pneumonitis in the right lower lobe and the suspicious lesion on the right hilum
are reaffirmed. The extent of pneumonitis shows a good correlation between MRI (e) and CT (k) even after 12 months. The suspicious diffusion
restriction in the right hilum (f) can still be clearly seen, whereas in CT (l) a delineation is much more difficult. After the study, the patient
developed a right hilar recurrence
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were again close to the PR threshold. One patient had
PD in both CT and DWI.
The median percentage size changes of the tumor
showed no significant difference between CT (− 20.00
[− 23.00–82.75]) and DWI (− 39.53 [− 63.56–153.6) (p >
0.99).
Assessment of tumor volume
Figure 3 shows the development of tumor volume in CT
and DWI over the course of time.
Available CT and DWI data sets as well as comparable
data pairs are the same as in the assessment of tumor
size using RECIST 1.1/LD.
At 3 (p = 0.5771), 6 (p = 0.3125) and 12 (p = 0.2500)
months, there was no significant difference between CT
and DWI in terms of tumor volume. At 3months, the
percentage change in tumor volume was − 84.16 [−
95.74 - -36.43) on CT and − 91.73 [− 95.84 - -59.69] on
DWI. At 6 months, the percent change in tumor volume
was − 29.87 [− 83.96–228.6) on CT and − 34.19 [−
88.79–204.5] on DWI. And at 12 months, the percent
change in tumor volume was − 68.29 [− 95.88–564.7] on
CT and – 89.11 [− 98.26–427.1] on DWI.
Assessment of RILT
Table 2 shows by means of a contingency table the fre-
quency distribution of the pneumonitis scores deter-
mined in CT and MRI (T2-TSE).
A total of 13 data pairs were comparable after 3
months. At the 6 months follow up 10 data pairs were
comparable and at the 12months follow up there were 6
data sets available.
The classification of pneumonitis on CT and MRI cor-
related very well after 3 months (r = 0.88). The median
score was 1 [0–3] (mean with Std. deviation 1.15 ± 1.28)
on CT and 1 on MRI [0–2] (mean with Std. deviation
0.92 ± 0.95). After 6 months, there was only a moderate
correlation between the two modalities (r = 0.50). The
median score was 3.0 [0–3] (mean with Std. deviation
2.27 ± 1.01) on CT and 1.5 on MRI [0–3] (mean with
Std. deviation 1.5 ± 0.85). After 12 months, the
correlation was again very good (r = 0.90). The median
score was 2.5 [0–3] (mean with Std. deviation 1.83 ±
1.47) on CT and 2.0 on MRI [0–3] (mean with Std. devi-
ation 1.6 ± 1.37).
Functional imaging/ADC
The mean ADC values of each patient in the course of
the 4 timepoints are shown in Fig. 4 Panel a. Averaging
the ADC values over the 4 time points revealed no sta-
tistically significant difference for either the ADC mean
(p = 0.15) or the ADC maximum (p = 0.16) (Fig. 4 Panel
c/d). However, an increasing trend could be observed for
both values: ADC mean (0-months: 1113 ± 127.0, 3
months 1500 ± 144.6, 6 months 1258 ± 104.8 and 12
months 1421 ± 251.5) and ADC MAX (0-months:
1533 ± 133.9, 3 months 1940 ± 147.9, 6 months 1797 ±
150.9 and 12months 2100 ± 477.8). Finally, the patient
collective was divided into two groups: one with therapy
response (PR) and another one with progressive disease
(PD). However, it was not possible to include all pa-
tients, since not every patient could be clearly assigned
to one of the two groups. The group with response to
therapy had a higher ADC value at all times than the
group with PD (Fig. 4 Panel b). However, the difference
was not statistically significant (p = 0.13).
Interobserver variability
ICC for continuous data, longest diameter, yielded an
excellent agreement (ICC = 0.996; 95% CI, 0.990–0.998).
Weighted kappa for ordinal data, RILT Score, resulted
in a substantial agreement 0.780 (95% CI, 0.592–0.959).
Discussion
MRI of the chest had long been technically challenging
due to the movement and breathing artifacts of the thor-
acic organs as well as the susceptibility artifacts caused
by the interfaces between different tissues and the over-
all low proton density of the lung [17].
The continuous technical development in MRI with
fast imaging techniques, resulting in protocols with scan
Table 2 Comparison of the absolute percentages of the CT and MRI pneumonitis score at 3, 6 and 12 months after the end of
treatment. After 3 and 12 months there was a very good correlation. However, there was only a moderate correlation after 6
months. Overall, the score on MRI tends to be slightly lower than in the corresponding CT. Absolute frequencies are written in
parenthesis behind the corresponding percentage value




Percentage of grand total MRI 0 MRI 1 MRI 2 MRI 3 MRI 0 MRI 1 MRI 2 MRI 3 MRI 0 MRI 1 MRI 2 MRI 3
CT 0 35.71 (5) 7.14 (1) 0.00 (0) 0.00 (0) 10.00 (1) 0.00 (0) 0.00 (0) 0.00 (0) 33.33 (2) 0.00 (0) 0.00 (0) 0.00 (0)
CT 1 7.14 (1) 7.14 (1) 0.00 (0) 0.00 (0) 0.00 (0) 10.00 (1) 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0) 0.00 (0)
CT 2 0.00 (0) 0.00 (0) 14.29 (2) 0.00 (0) 0.00 (0) 10.00 (1) 20.00 (2) 0.00 (0) 0.00 (0) 0.00 (0) 16.67 (1) 0.00 (0)
CT 3 0.00 (0) 0.00 (0) 28.57 (4) 0.00 (0) 0.00 (0) 20.00 (2) 20.00 (2) 10.00 (1) 0.00 (0) 0.00 (0) 16.67 (1) 33.33 (2)
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times between 15 and 30 min [18], has made chest MRI
an interesting alternative to CT [19, 20]. Regarding the
low evidence of appropriate follow-up examinations in
NSCLC, especially after chemoradiation [8], chest MRI
might be the future solution. Our study is one of the
first longitudinal investigations comparing CT and MRI
after chemoradiation of NSCLC regarding morphological
and functional parameters.
Prior studies have mainly focused on pretreatment
comparison of CT or PET/CT and MRI [13, 18].
Fleckenstein et al. already demonstrated a high level of
concordance between the pretreatment tumor volumes
of PET-CT and DWI for radiotherapy-planning [13].
FDG-PET/CT has a high diagnostic accuracy in the
detection of local tumor recurrences [21] and is often
used, when – based on the follow-up CT – a recurrence
is suspected [22]. Nevertheless, FDG-uptake is also en-
hanced in lung regions which show severe RILT. There-
fore, the diagnosis of local lung recurrences in areas of
RILT might be impaired in such cases. Also, FDG-PET/
CT is usually more expensive and less available than
DWI and thus contraindicated as a routine measure in
the follow-up due to economic and logistic reasons.
We observed no statistically significant difference re-
garding the percentage change of the longest longitudinal
diameter between CT and DWI at 3, 6 and 12months
(Fig. 1). The spread of the measurements within the two
modalities can be explained most easily on the different
initial tumor sizes and its responses. An inverse tumor re-
sponse between CT and DWI was not observed. This is
also reflected by the classification of the tumor response
according to RECIST 1.1. There was a high concordance
between DWI and CT regarding therapy response after 3
months resulting in PR (n = 6), SD (n = 3) and PD (n = 1).
In the three discrepant cases only a few percentage points
were missing for the transition from PR to SD or SD to
PR. However, at 6 and 12months, there is a diminishing
correspondence of CT and DWI in terms of tumor re-
sponse. This observation may have multifactorial causes,
such as RILT with limited sensitivity of CT scans, de-
ceased patients and missed appointments. However, in the
follow-up at 6 and 12months in individual cases, the DWI
Fig. 4 Panel a shows the course of the ADC values for all patients (cases 1–14; case 12 with two lesions) separately. Panel b divided the patients
into a Progress (PD) and a Remission (PR) group. Patients in the progress group showed lower ADC values initially and throughout the course. In
panel c and d, the mean and maximum (MAX) ADC values of all patients were averaged seperatly for each time point and presented in follow-
up. In both Panel c and d there is a tendency for the ADC value to increase over time. Values in Panel c and d are displayed as mean and SEM
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detected recurrences earlier than CT or excluded them
with greater certainty (Table 1 [Cases 2 and 7] and Fig. 2).
These results are in line with the study published in May
2019 by Usuda et al. [23]. In their study DWI was more
accurate than CT in determining a response of recurrent
lesions of lung cancer to chemotherapy and/or radiother-
apy. Consistent with our study, they concluded that DWI
may be able to identify residual cancer, thereby improving
specificity and sensitivity.
Conventional response criteria like RECIST 1.1 have
some limitations. There is an ongoing debate how accur-
ate a unidimensional measurement can represent the real
tumor burden due to varying and often highly irregular
tumor shapes. Meanwhile, several studies have demon-
strated that volume measurement in lung tumors is more
reproducible than size measurement [24, 25]. In addition,
the study by Zhang et al. proves that DWI has a more pre-
cise delineation of lung cancer while exhibiting higher re-
producibility [26]. In our study there was no significant
difference between tumor volumes as determined by CT
and DWI at any of the three follow-up dates. The tumor
volumes in the DWI tended to be slightly smaller than in
their CT counterparts. We identified the more precise de-
marcation of the tumor against atelectatic lung tissue and
parenchymal changes in pneumonitis as the major cause
for this discrepancy. There is a lack of data comparing CT
and DWI tumor volumes in the course of therapy after
chemoradiation. A comparable study by Weiss et al. deter-
mined significantly larger tumor volumes by CT as com-
pared to DWI in patients after chemoradiation [27].
However, the results are only partially comparable to the
data presented here, since the working group around
Weiss et al. chose follow up assessments at 3 and 6 weeks,
thus focusing on early changes.
In the future, we will be particularly challenged by the
assessment of tumor process under immunotherapy.
However, initial studies are already showing the advan-
tages of MRI/DWI in the assessment of tumor response
already [28, 29].
In addition to assessing tumor response, the applied
imaging modality should reliably indicate RILT. RILT
typically occurs as early as 4 to 12 weeks after treatment
and may transform into radiation fibrosis (which may
also occur independently) after 6 months or later [30].
Although clinically debilitating pneumonitis (grade ≥ 3)
after radiotherapy develops in less than 10 % of patients
[31], imaging in commonly used scores, such as the
LENT-SOMA Score from the European Organization
for Research and Treatment of Cancer (EORTC) [32],
plays a role in diagnosis and therefore therapy. Regard-
ing the evaluation of RILT, some groups use functional
investigations in MRI with xenon gas with quite impres-
sive results [33]. Meanwhile, the parenchymal structure
of the lungs can be adequately assessed by MRI, as was
shown by Sileo et al. in patients suffering from cystic fi-
brosis [34]. To our knowledge, we hereby present the
first investigation to examine the correlation of RILT
scores determined by CT and MRI, respectively respira-
tory gated T2-weighted sequence, over a period of 1
year. At 3 and 12months a high correlation of the RILT
scores was found. However, at the early stage of fibrosis
development at 6 months, only a moderate correlation
was shown between the two modalities. At this stage,
the CT achieved a higher score than the MRI, which
may be a hint for its earlier detection of reticular lung
parenchyma changes. Overall, however, it can be con-
cluded that respiratory gated T2-weighted sequence can
adequately assess the ultrastructure of the lungs in the
early and late phase after chemoradiation to diagnose or
exclude RILT. Differentiating between treatment effects
like RILT or tumor-atelectasis-complex and residual or
recurrent tumor, is challenging [35]. Like aforemen-
tioned, in some cases of the presented group, by using
DWI, as compared to CT, we were able to delineate re-
currences earlier and to more reliably rule out recur-
rence within lung parenchyma altered by RILT (Fig. 2).
These results are in line with a study of Munoz-
Schuffenegger et al. in which they could prove that DWI
confirmed the suspicion of local recurrence in patients
with highly suspicious CT scans [36]. Furthermore,
DWI/ADC not only provides these important additional
informations but might also be a prognostic factor.
Looking at the individual mean ADC values of patients
over the time course, no clear pattern could be observed
in our study (Fig. 4a). However, averaging the ADC
values of all patients at each time point mean and max-
imum ADC showed a tendency to increase (Fig. 4c/d).
Our results are consistent with prior studies which dem-
onstrated a significant ADC increase after chemoradia-
tion and chemotherapy [27, 37, 38]. Weiss et al. showed
that patients with survival < 12 months had a lower in-
crease in ADC values compared to longer-lived patients
[27]. Sampath et al. could demonstrate that an ADC in-
crease of 40% at 1 month after SBRT for NSCLC is asso-
ciated with a higher rate of local failure [39]. In contrast,
non-responders in the study by Chang et al. had a slight
decrease in ADC, whereas responders had a relatively
steeper increase of ADC [37]. As opposed to the latter
data, after formation of a PD and PR group, we were un-
able to detect a significant increase or decrease in the
mean ADC between the two groups (Fig. 4b), which
could be due to the small sample size. However, both
the pretherapeutic and the mean ADC values over the
course tend to be lower in non-responders (PD group).
In agreement with our findings, Shintani et al. and
Iizuka et al. found that low ADC on pre-treatment MRI
were associated with local recurrence and poor disease
progression [40, 41]. Yet, Ohno et al. reported
Jagoda et al. Cancer Imaging           (2021) 21:15 Page 9 of 11
contradictory findings in patients in whom higher ADC
on pretreatment MRI were significantly associated with
poor prognosis [42].
The discrepancies in the predictive power of the ADC
may in part be due to the non-uniform measurement.
Depending on the study, the mean, minimum or max-
imum ADC value is used. Furthermore, until now there
is no clear definition of where within the tumor one
should place the ADC ROI. Further studies are needed
to establish a uniform and reproduceable measurement
of the ADC and thus to substantiate its prognostic value.
Beside of all of these capabilities MRI offers in imaging
of the NSCLC, the acquisition time of this modality has
to be viewed critically especially in comparison with CT.
As mentioned in the first section of the Discussion, the
MRI protocol takes about 15–30min (median duration
33min, range [max to min] 19 min to 1 h and 13min).
Compared to a CT scan of the thorax with an acquisi-
tion time of only a few seconds for the actual scan and a
few minutes for the entire examination, this is of course
a considerable effort, especially for patients with im-
paired lung function. However, the MRI protocol can
certainly be optimized by removing, respectively limiting
the time-consuming breath-triggered T2-TSE to the tar-
get areas, because acquisition of the whole thorax can
take between 15 and 30min depending on the patient’s
body height and breathing variability. If assessment of
the ultra-structure of the lung is not required, DWI/
ADC in combination with T2-HASTE, both only taking
about 5 min for image acquisition, could be a solution
for thorax imaging regarding T and N stadium.
Our study had some limitations. First, it is a single center
study with a small number of patients. Additionally, some
patients did not complete scanning schedule and we can’t
exclude the possibility that this might have skewed the
results.
Conclusion
In conclusion we present an initial longitudinal study,
which demonstrates that after chemoradiation therapy re-
sponse determined by RECIST 1.1 and tumor volume
measurement can be done by DWI yielding similar results
to CT. In addition, the presented study is one of the first to
describe typical changes of RILT in the early and late phase
as diagnosed with MRI as compared to the gold standard
of CT. Thus, MRI including DWI, bears a strong po-
tential for improved detection of an inadequate re-
sponse to radiotherapy or early recurrences. In regard
to the potential prognostic value of ADC measure-
ments further investigations are necessary.
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